Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
Carolyn Dosen PhilpottChristopher A DroegeMolly E DroegeDaniel P HealyJoshua D CourterNeil E ErnstNicole J HargerMadeline J FoertschJessica B WinterKristen E CarterSuzanne L Van FleetKrishna AthotaEric W MuellerPublished in: Pharmacotherapy (2019)
Extended-infusion cefepime dosing in critically ill patients receiving CRRT successfully attained 100% fT > MIC8 in all patients and an appropriate fCmin /MIC8 for both first and steady-state doses. All but one patient achieved 100% fT > 4 × MIC8 at steady state. No significant differences were observed in PK properties between first and steady-state doses among or between patients. It may be reasonable to initiate an empiric or definitive regimen of EI cefepime in critically ill patients receiving concurrent CRRT who are at risk for resistant organisms. Further research is needed to identify the optimal dosing regimen of EI cefepime in this patient population.